Relationships between adipokines, biomarkers of endothelial function and inflammation and risk of type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 105, Issue 2, 2014, Pages 231-238

  Julia, C ^a   Czernichow, S ^b,c,d   Charnaux, N ^e   Ahluwalia, N ^a   Andreeva, V ^a   Touvier, M ^a   Galan, P ^a   Fezeu, L ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d HÔPITAL AMBROISE PARÉ   (France)

^e HÔPITAL JEAN VERDIER   (France)

Author keywords

Adipokines; Diabetes mellitus, type 2; E selectin; Inflammation; Intercellular cell adhesion molecule 1; Vascular cell adhesion molecule 1

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); DISEASE ASSOCIATION; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; INTEGRATED DISCRIMINATION IMPROVEMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; STATISTICAL CONCEPTS; VASCULAR ENDOTHELIUM;

ADIPOKINES; DIABETES MELLITUS, TYPE 2; E-SELECTIN; INFLAMMATION; INTERCELLULAR CELL ADHESION MOLECULE-1; VASCULAR CELL ADHESION MOLECULE-1;

ADIPOKINES; ADIPONECTIN; ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHEMOKINE CCL2; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; E-SELECTIN; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; LEPTIN; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS;

EID: 84906053616     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.05.001     Document Type: Article

References (33)

1. Sattar N., Wannamethee S.G., Forouhi N.G. Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities. Diabetologia 2008, 51:926-940.
2. Czernichow S., Couthouis A., Bertrais S., Vergnaud A.C., Dauchet L., Galan P., et al. Antioxidant supplementation does not affect fasting plasma glucose in the Supplementation with Antioxidant Vitamins and Minerals (SU.VI.MAX) study in France: association with dietary intake and plasma concentrations. Am J Clin Nutr 2006, 84:395-399.
3. Czernichow S., Vergnaud A.C., Galan P., Arnaud J., Favier A., Faure H., et al. Effects of long-term antioxidant supplementation and association of serum antioxidant concentrations with risk of metabolic syndrome in adults. Am J Clin Nutr 2009, 90:329-335.
4. Ley S.H., Harris S.B., Connelly P.W., Mamakeesick M., Gittelsohn J., Hegele R.A., et al. Adipokines and incident type 2 diabetes in an Aboriginal Canadian [corrected] population: the Sandy Lake Health and Diabetes Project. Diabetes Care 2008, 31:1410-1415.
5. Li S., Shin H.J., Ding E.L., van Dam R.M. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009, 302:179-188.
6. Thorand B., Zierer A., Baumert J., Meisinger C., Herder C., Koenig W. Associations between leptin and the leptin/adiponectin ratio and incident type 2 diabetes in middle-aged men and women: results from the MONICA/KORA Augsburg study 1984-2002. Diabet Med 2010, 27:1004-1011.
7. Dehghan A., Kardys I., de Maat M.P., Uitterlinden A.G., Sijbrands E.J., Bootsma A.H., et al. Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 2007, 56:872-878.
8. Krakoff J., Funahashi T., Stehouwer C.D., Schalkwijk C.G., Tanaka S., Matsuzawa Y., et al. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003, 26:1745-1751.
9. Laugsand L.E., Asvold B.O., Vatten L.J., Romundstad P.R., Wiseth R., Hveem K., et al. Metabolic factors and high-sensitivity C-reactive protein: the HUNT study. Eur J Prev Cardiol 2012, 19:1101-1110.
10. Meigs J.B., Hu F.B., Rifai N., Manson J.E. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004, 291:1978-1986.
11. Munzberg H., Myers M.G. Molecular and anatomical determinants of central leptin resistance. Nat Neurosci 2005, 8:566-570.
12. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
13. Wellen K.E., Hotamisligil G.S. Inflammation, stress, and diabetes. J Clin Invest 2005, 115:1111-1119.
14. Czernichow S., Greenfield J.R., Galan P., Bastard J.P., Charnaux N., Samaras K., et al. Microvascular dysfunction in healthy insulin-sensitive overweight individuals. J Hypertens 2010, 28:325-332.
15. Han S.H., Quon M.J., Koh K.K. Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction. Curr Opin Lipidol 2007, 18:58-65.
16. Balkau B., Lange C., Fezeu L., Tichet J., de Lauzon-Guillain B., Czernichow S., et al. Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2008, 31:2056-2061.
17. Hercberg S., Galan P., Preziosi P., Bertrais S., Mennen L., Malvy D., et al. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med 2004, 164:2335-2342.
18. Kesse-Guyot E., Fezeu L., Jeandel C., Ferry M., Andreeva V., Amieva H., et al. French adults' cognitive performance after daily supplementation with antioxidant vitamins and minerals at nutritional doses: a post hoc analysis of the Supplementation in Vitamins and Mineral Antioxidants (SU.VI.MAX) trial. Am J Clin Nutr 2011, 94:892-899.
19. Pencina M.J., D'Agostino R.B., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172.
20. ® Macro to Compute Added Predictive Ability of New Markers Predicting a Dichotomous Outcome 2010, SouthEast SAS Users Group (SESUG). http://analytics.ncsu.edu/sesug/2010/SDA07.Kennedy.pdf.
21. SAS support SAS %ROC macro 2012, SAS support, Cary, NC, Available from: http://support.sas.com/kb/25/addl/fusion_25017_6_roc.sas.txt.
22. Schmidt M.I., Duncan B.B., Vigo A., Pankow J.S., Couper D., Ballantyne C.M., et al. Leptin and incident type 2 diabetes: risk or protection. Diabetologia 2006, 49:2086-2096.
23. Havel P.J. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 2004, 53(Suppl. 1):S143-S151.
24. Herder C., Baumert J., Thorand B., Koenig W., de Jager W., Meisinger C., et al. Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-2002. Diabetologia 2006, 49:921-929.
25. Sell H., Eckel J. Monocyte chemotactic proten-1 and its vole in insulin resistance. Curr Opin Lipidol 2007, 18:258-262.
26. Chao C., Song Y., Cook N., Tseng C.H., Manson J.E., Eaton C., et al. The lack of utility of circulating biomarkers of inflammation and endothelial dysfunction for type 2 diabetes risk prediction among postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med 2010, 170:1557-1565.
27. Raynor L.A., Pankow J.S., Duncan B.B., Schmidt M.I., Hoogeveen R.C., Pereira M.A., et al. Novel risk factors and the prediction of type 2 diabetes in the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 2013, 36:70-76.
28. Abbasi A., Peelen L.M., Corpeleijn E., van der Schouw Y.T., Stolk R.P., Spijkerman A.M.W., et al. Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study. Br Med J 2012, 345.
29. Herder C., Kowall B., Tabak A.G., Rathmann W. The potential of novel biomarkers to improve risk prediction of type 2 diabetes. Diabetologia 2014, 57:16-29.
30. Sattar N. Biomarkers for diabetes prediction, pathogenesis or pharmacotherapy guidance? Past, present and future possibilities. Diabet Med 2012, 29:5-13.
31. Touvier M., Fezeu L., Ahluwalia N., Julia C., Charnaux N., Sutton A., et al. Association between pre-diagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. Am J L.A. RaynEpidemiol 2013, 177:3-13. http://www.ncbi.nlm.nih.gov/pubmed/23171880.
32. Laughlin G.A., Barrett-Connor E., May S., Langenberg C. Association of adiponectin with coronary heart disease and mortality - The Rancho Bernardo Study. Am J Epidemiol 2007, 165:164-174.
33. Langenberg C., Bergstrom J., Scheidt-Nave C., Pfeilschifter J., Barrett-Connor E. Cardiovascular death and the metabolic syndrome - role of adiposity-signaling hormones and inflammatory markers. Diabetes Care 2006, 29:1363-1369.